- Home
- Na Natural Killer Nk Cell Therapeutics Market
NA Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
- Published Date: September, 2022 | Report ID: CLS-505 | No of pages: 176 | Format:
North America natural killer (NK) cell therapeutics market is projected to register a CAGR of 40.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
North America Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the North America natural killer (NK) cell therapeutics market are:
Increase in patient population with chronic diseases
Rise in awareness about immunotherapies
In usage of natural killer (NK) cells for the treatment of cancer and infectious diseases
Market Players:
The key market players for North America natural killer (NK) cell therapeutics market are listed below:
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Kiadis Pharma
Cytovia Therapeutics
Nkarta, Inc.
Nektar
ImmunityBio, Inc.
Brink Biologics, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
PersonGen BioTherapeutics
Innate Pharma, Inc.
INmuneBIO
Gamida Cell
Acepodia Inc.
Affimed GmbH
Multimmune GmbH
iCell Gene Therapeutics
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals Inc.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 30 1.1 OBJECTIVES OF THE STUDY 30 1.2 MARKET DEFINITION 30 1.3 OVERVIEW OF NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET 30 1.4 LIMITATIONS 32 1.5 MARKETS COVERED 33 2 MARKET SEGMENTATION 35 2.1 MARKETS COVERED 35 2.2 GEOGRAPHICAL SCOPE 36 2.3 YEARS CONSIDERED FOR THE STUDY 37 2.4 CURRENCY AND PRICING 37 2.5 DBMR TRIPOD DATA VALIDATION MODEL 38 2.6 MULTIVARIATE MODELLING 41 2.7 THERAPEUTICS LIFELINE CURVE 41 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42 2.9 DBMR MARKET POSITION GRID 43 2.10 SECONDARY SOURCES 45 2.11 ASSUMPTIONS 45 3 EXECUTIVE SUMMARY 46 3.1 EPIDEMIOLOGY 51 3.2 PESTEL ANALYSIS 52 3.3 PORTERS FIVE FORCES MODEL 53 3.4 INDUSTRIAL INSIGHTS: 54 3.5 PIPELINE ANALYSIS 56 4 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: REGULATIONS 57 5 MARKET OVERVIEW 59 5.1 DRIVERS 61 5.1.1 INCREASE IN USAGE OF NATURAL KILLER (NK) CELLS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 61 5.1.2 INCREASE IN PATIENT POPULATION WITH CHRONIC DISEASES 61 5.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 62 5.1.4 ADOPTION OF NATURAL KILLER (NK) CELL THERAPY IN EMERGING MARKETS 62 5.2 RESTRAINTS 63 5.2.1 LACK OF SPECIFICITY AND POOR IN-VIVO SURVIVAL OF THE CELLS 63 5.2.2 ADVERSE SIDE EFFECTS OF THERAPIES 63 5.2.3 HIGH COST ASSOCIATED WITH THE THERAPIES 64 5.3 OPPORTUNITIES 65 5.3.1 ADVANCEMENT IN NATURAL KILLER (NK) CELL THERAPIES 65 5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 65 5.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 66 5.4 CHALLENGES 66 5.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 66 5.4.2 LACK OF SPECIFIC TREATMENT BY NATURAL KILLER (NK) CELLS 67 5.4.3 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 67 6 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS 69 6.1 OVERVIEW 70 6.2 NK CELL THERAPIES 73 6.3 NK CELL DIRECTED ANTIBODIES 73 7 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES 75 7.1 OVERVIEW 76 7.2 ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 79 7.3 BISPECIFIC ANTIBODIES 80 8 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION 81 8.1 OVERVIEW 82 8.2 CANCER 85 8.2.1 SOLID TUMORS 86 8.2.2 HEMATOLOGIC MALIGNANCIES 86 8.2.2.1 MULTIPLE MYELOMA 87 8.2.2.2 ACUTE MYELOID LEUKEMIA (AML) 87 8.2.2.3 LYMPHOMA 87 8.2.2.4 OTHERS 87 8.2.3 OTHERS 87 8.3 IMMUNOPROLIFERATIVE DISORDERS 87 8.4 ACUTE INFECTIOUS DISEASES 88 8.5 GASTROINTESTINAL DISEASES 88 8.6 OTHERS 89 9 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 91 9.1 OVERVIEW 92 9.2 HOSPITALS 95 9.3 SPECIALTY CLINICS 95 9.4 RESEARCH & ACADEMIC INSTITUTES 96 10 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 98 10.1 OVERVIEW 99 10.2 HOSPITAL PHARMACIES 102 10.3 DIRECT TENDER 102 10.4 OTHERS 103 11 NORTH AMERICA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION 104 11.1 NORTH AMERICA 105 11.1.1 U.S. 112 11.1.2 CANADA 115 11.1.3 MEXICO 118 12 NORTH AMERICA NATURAL KILLER (NK) CELLS THERAPEUTICS MARKET, COMPANY LANDSCAPE 121 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 121 13 SWOT ANALYSIS 122 14 COMPANY PROFILE 123 14.1 MERCK KGAA 123 14.1.1 COMPANY SNAPSHOT 123 14.1.2 RECENT FINANCIALS 123 14.1.3 PRODUCT PORTFOLIO 124 14.1.4 RECENT DEVELOPMENTS 124 14.2 BRISTOL-MYERS SQUIBB COMPANY 126 14.2.1 COMPANY SNAPSHOT 126 14.2.2 RECENT FINANCIALS 126 14.2.3 PRODUCT PORTFOLIO 127 14.2.4 RECENT DEVELOPMENTS 127 4.3 GLYCOSTEM 129 14.3.1 COMPANY SNAPSHOT 129 14.3.2 PRODUCT PORTFOLIO 129 14.3.3 RECENT DEVELOPMENTS 129 14.4 INNATE PHARMA, INC. 131 14.4.1 COMPANY SNAPSHOT 131 14.4.2 REVENUE ANALYSIS 131 14.4.3 PRODUCT PORTFOLIO 132 14.4.4 RECENT DEVELOPMENTS 132 14.5 REGENERON PHARMACEUTICALS INC. 134 14.5.1 COMPANY SNAPSHOT 134 14.5.2 RECENT FINANCIALS 134 14.5.3 PRODUCT PORTFOLIO 135 14.5.4 RECENT DEVELOPMENTS 135 14.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED 136 14.6.1 COMPANY SNAPSHOT 136 14.6.2 RECENT FINANCIALS 136 14.6.3 PRODUCT PORTFOLIO 137 14.6.4 RECENT DEVELOPMENTS 137 14.7 INMUNEBIO 138 14.7.1 COMPANY SNAPSHOT 138 14.7.2 REVENUE ANALYSIS 138 14.7.3 PRODUCT PORTFOLIO 139 14.7.4 RECENT DEVELOPMENTS 139 14.8 KIADIS PHARMA 141 14.8.1 COMPANY SNAPSHOT 141 14.8.2 REVENUE ANALYSIS 141 14.8.3 PRODUCT PORTFOLIO 142 14.8.4 RECENT DEVELOPMENTS 142 14.9 ACEPODIA INC. 144 14.9.1 COMPANY SNAPSHOT 144 14.9.2 PRODUCT PORTFOLIO 144 14.9.3 RECENT DEVELOPMENTS 144 14.10 AFFIMED GMBH 146 14.10.1 COMPANY SNAPSHOT 146 14.10.2 RECENT FINANCIALS 146 14.10.3 PRODUCT PORTFOLIO 147 14.10.4 RECENT DEVELOPMENTS 147 14.11 BIOHAVEN PHARMACEUTICALS 149 14.11.1 COMPANY SNAPSHOT 149 14.11.2 REVENUE ANALYSIS 149 14.11.3 PRODUCT PORTFOLIO 150 14.11.4 RECENT DEVELOPMENTS 150 14.12 BRINK BIOLOGICS, INC. 151 14.12.1 COMPANY SNAPSHOT 151 14.12.2 PRODUCT PORTFOLIO 151 14.12.3 RECENT DEVELOPMENT 151 14.13 CYTOVIA THERAPEUTICS 152 14.13.1 COMPANY SNAPSHOT 152 14.13.2 PRODUCT PORTFOLIO 152 14.13.3 RECENT DEVELOPMENTS 152 14.14 EMERCELL 154 14.14.1 COMPANY SNAPSHOT 154 14.14.2 PRODUCT PORTFOLIO 154 14.14.3 RECENT DEVELOPMENTS 154 14.15 FATE THERAPEUTICS 155 14.15.1 COMPANY SNAPSHOT 155 14.15.2 REVENUE ANALYSIS 155 14.15.3 PRODUCT PORTFOLIO 156 14.15.4 RECENT DEVELOPMENTS 156 14.16 GAMIDA CELL 158 14.16.1 COMPANY SNAPSHOT 158 14.16.2 PRODUCT PORTFOLIO 158 14.16.3 RECENT DEVELOPMENTS 159 14.17 ICELL GENE THERAPEUTICS 160 14.17.1 COMPANY SNAPSHOT 160 14.17.2 PRODUCT PORTFOLIO 160 14.17.3 RECENT DEVELOPMENT 160 14.18 IMMUNITYBIO, INC. 161 14.18.1 COMPANY SNAPSHOT 161 14.18.2 REVENUE ANALYSIS 161 14.18.3 PRODUCT PORTFOLIO 162 14.18.4 RECENT DEVELOPMENTS 162 14.19 MULTIMMUNE GMBH 163 14.19.1 COMPANY SNAPSHOT 163 14.19.2 PRODUCT PORTFOLIO 163 14.19.3 RECENT DEVELOPMENTS 163 14.20 NEKTAR 164 14.20.1 COMPANY SNAPSHOT 164 14.20.2 REVENUE ANALYSIS 164 14.20.3 PRODUCT PORTFOLIO 165 14.20.4 RECENT DEVELOPMENTS 165 14.21 NKARTA, INC. 166 14.21.1 COMPANY SNAPSHOT 166 14.21.2 PRODUCT PORTFOLIO 166 14.21.3 RECENT DEVELOPMENTS 166 14.22 PERSONGEN BIOTHERAPEUTICS 168 14.22.1 COMPANY SNAPSHOT 168 14.22.2 PRODUCT PORTFOLIO 168 14.22.3 RECENT DEVELOPMENTS 168 14.23 PHIO PHARMACEUTICALS 170 14.23.1 COMPANY SNAPSHOT 170 14.23.2 PRODUCT PORTFOLIO 170 14.23.3 RECENT DEVELOPMENTS 170 15 QUESTIONNAIRE 172 16 RELATED REPORTS 176Segmentation
Short Description North America Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029 Market Definition: Natural killer (NK) cells are the large granular lymphocytes which have the ability to quickly respond to a pathological challenge. Natural killer cells are the important component of innate immune system and play an important role in generating immune response against the malignancies and infectious diseases caused by viral pathogens. Natural killer (NK) cells have been recognized to induce direct killing of targeted cells involving cancer cells. These have the ability to recognize the multitude of infected cells without being dependent on a single antigen expressing cells. NK cells secrete cytokines and chemokines which recruit other immune cells such as T cells and B cells which enhances the immune response against the tumor cells. As Natural killer (NK) cells do not express T cell receptors, they induce low risk of graft-versus-host disease. The effectiveness of NK cells therapies can be also be enhanced by genetically modified the NK cells so as to obtain highly specific and persistent cell lines. NK cell therapies can also be used with mono-clonal antibodies and T-cell therapies which again enhances its anti-tumor activity. Increase in usage of natural killer cells for the treatment of cancer and infectious disease is a key factor responsible for market growth. Along with this rise in patients population with chronic disease and rise in the awareness about immunotherapies boosting the market growth. Market Segmentation: Natural killer (NK) cell therapeutics market is categorized into four notable segments which are based on therapeutics, approaches, application, end user, and distribution channel. On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies. On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others. On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others. Market Players The key market players for natural killer (NK) cell therapeutics market are listed below: Merck KGaA Bristol-Myers Squibb Company Glycostem Kiadis Pharma Cytovia Therapeutics Nkarta, Inc. Nektar ImmunityBio, Inc. Brink Biologics, Inc. Biohaven Pharmaceuticals Fate Therapeutics EMERcell Phio Pharmaceuticals PersonGen BioTherapeutics Innate Pharma, Inc. INmuneBIO Gamida Cell Acepodia Inc. Affimed GmbH Multimmune GmbH iCell Gene Therapeutics Takeda Pharmaceutical Company Limited Regeneron Pharmaceuticals Inc.Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.